
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-09-01-2009
- Volume 21
- Issue 9
Strength in numbers
Merger, union, alliance, partnership, collaboration: five words that ultimately suggest the strengthening of something.
Merger, union, alliance, partnership, collaboration: five words that ultimately suggest the strengthening of something. Every company, no matter how large or small, must undertake at least one of these strategies to secure its longevity.
Fedra Pavlou
Indeed, no one can escape the frenzy of activity that has been taking place in the pharmaceutical industry lately. Such unions have, of course, been commonplace; however, it's been quite interesting to see pharma's response to the threats it currently faces, including, amongst others, the economic downturn, dry development pipelines and generic competition. The reaction of these already giant corporations has been to form alliances to grow an existing division, to diversify, to shed an underperforming unit, to secure a solid pipeline, and so on. Whatever the secondary reason, the primary reason has always been to secure growth, to strengthen, to improve and to survive.
At Pharmaceutical Technology Europe, we too have undertaken such a union; we have united with our US colleagues at Pharmaceutical Technology to bring our readers a tool that we believe is the best online resource for pharmaceutical manufacturing professionals. We hope that you agree with us!
Launched last month, the new
I would welcome your comments and suggestions on the new
Many thanks and best wishes,
Articles in this issue
about 16 years ago
The combination drugs debate: unstable and unpatentableabout 16 years ago
Expansion planabout 16 years ago
The combination drugs debate: Incompatibility problems can be overcomeabout 16 years ago
Integrating PAT into biopharmaceutical research: a case studyabout 16 years ago
What to consider when expanding businesses into North Americaabout 16 years ago
Is another ODT excipient necessary?about 16 years ago
Embryonic stem cells: the moral dilemma of patentability and fundingabout 16 years ago
The benefits of risk-based analyses during system validationabout 16 years ago
NewsNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





